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TRANSLATIONAL RELEVANCE:
To date, next generation sequencing has been completed for a substantial number of primary breast tumours and provides an in depth understanding of the biology and heterogeneity of this disease.
Here primary tumours together with matched nodal and liver metastatic patient tumours have been sequenced, offering the first in depth view of the transcriptomic changes occurring during disease progression. Patient heterogeneity was strongly evident in both primary and metastatic tumours. In addition, common adaptations in cell-cell communication were detected as metastatic endocrineresistant disease took hold. These findings emphasise the need for ongoing personalised medicine throughout disease management. In particular, it is important to re-evaluate the biology of metastatic disease, following treatment intervention, in order to monitor adaptations and identify the optimal treatment strategy.
INTRODUCTION
The vast majority of breast cancers are steroid receptor positive and depend on estrogen for growth.
The use of estrogen receptor modulators, such as tamoxifen and estrogen depletion strategies, including aromatase inhibitors, have been widely successful. Disease recurrence however is common, with between 10 and 25% of patients developing extensive local or distant metastases.
Most patients with metastases will succumb to their disease, as targeted therapies which provide significant clinical benefit remain elusive.
Metastatic breast cancer secondary to endocrine treatment is heterogeneous, ranging from discreet lesions to diffuse multi-organ disease. The dominant site of metastatic involvement can have a significant bearing on clinical outcome. Metastatic disease of the liver has been reported to be a predictor of poor outcome, with a median survival of 18 months (1), whereas metastatic burden confined to the bone is thought to be more indolent (2) .
Colonisation of the host organ is the ultimate step of a progressive disease path. Most breast cancer cells that enter the circulation and infiltrate distant organs die due to the hostile nature of the host microenvironment (3) . For metastatic growth to be established, disseminated breast cancer cells need to survive a period of latency, prolonged exposure to therapy and subsequently re-initiate growth when appropriate. Evidence of the impact of steroid treatment on tumour progression is emerging. Steroid receptor switching and in particular loss of the progesterone receptor (PgR), an estrogen receptor (ER) target, is observed in approximately 30% of patients (4, 5) . Furthermore, gain of function mutations in the ESR1 gene have been identified in metastatic lesions from endocrine treated patients (6, 7) .
The mechanisms required to enable cancer cells to overcome hostile forces and re-initiate growth at distant organs in endocrine treated patients have not been fully elucidated. Lessons from in vitro studies and murine models have provided important information regarding discrete tools employed by breast cancer cells to prosper at distant metastatic sites. For example, the CXCR4/SDF1 pairing has been identified as a mediator of metastatic cell survival in the bone (8, 9) ; transcriptional inhibitors of differentiation, Id1 and Id3, have been associated with lung metastasis (10, 11) ; and serpins, as metastatic functionaries in the brain (12) . However, to date, no global overview of gene expression alterations which are essential for successful colonisation of cells at metastatic sites in breast cancer patients has been undertaken.
To clearly define mediators of colonisation in endocrine treated patients we undertook gene expression analysis from sequential tumour samples. RNAseq analysis was performed on matched primary, nodal and distant metastatic tumours from breast cancer patients, all of whom had developed a liver metastasis following tamoxifen treatment. At a functional level, studies in xenograft models of endocrine resistant tumours were undertaken to examine the role of tamoxifen in the development of metastatic disease secondary to therapy resistance. Over represented pathways identified by the RNAseq analysis were further studied at the transcript and protein level in an expanded cohort of patients with metastases of multiple distant organs.
MATERIALS AND METHODS

Gene expression and bioinformatic analysis
Following ethical approval, formalin fixed paraffin embedded (FFPE) tumour samples were macrodissected to select regions with >70% tumour cells. RNA isolation was performed with High Pure FFPE RNA Micro Kit (Roche) and subjected to duplex specific thermostable nuclease (DSN) treatment. RNA Sequencing was performed by BGI (Hong Kong) using the Illumina HiSeq 2000 with >40million reads. Insufficient RNA was obtained from the nodal sample of patient one for sequencing. Reads were aligned to the hg19 genome using two different types of analysis: one for the differential expression and the other for use with the TCGA data. For the differential expression analysis, the reads were aligned using TopHat and genes were quantified using HTseq. For usage with TCGA data, the data was aligned using MapSplice and the genes were quantified using RSEM. cDNA was synthesised as previously described (13) . Gene expression was assessed using Taqman technology (Applied Biosystems) on the ABI PRISM 7500 platform with the following probes: EPPK1
Hs01104050_s1; COL4A2 Hs01098873_m1; COL4A1 Hs00266237_m1; SPDEF Hs01026050_m1; KRT19 Hs00761767_s1; AHDC1 Hs00210424_m1; NCOR2 Hs00196955_m1; AKAP8L
Hs00205106_m1. EIF2B Hs00426752_ml was used as an internal control. The comparative C T (ΔΔC T ) method was applied to analyse relative mRNA expression levels.
Immunohistochemistry
5μm tumour sections were deparaffinised and rehydrated as previously described (4). Antigen retrieval was performed with sodium citrate at pH6 or EDTA at pH9 (Ki67 by two independent assessors on a scale of 0-300 with 300 representing the highest intensity staining in 100% of cells.
Xenograft Studies
All mouse experiments were performed in accordance with the European Communities Council 
RESULTS
Gene expression profiles of breast cancer patients reflect the histopathology of the original primary tumour
RNA was extracted from matched breast cancer primary, node and liver metastatic tumour tissue from three tamoxifen treated luminal breast cancer patients. The patients represented the spectrum of the luminal classification, from luminal A (patient one) to luminal B2 (patient three) ( Table 1) .
Despite the diverse pathology of each of the primary breast tumours (Table 1 , Fig. 1A and Supplementary Fig. S1 ), positive steroid receptor status qualified each of the patients for adjuvant endocrine treatment.
Correspondence analysis of the sequenced RNA from the individual tissue samples revealed that each of the sequential patient samples clustered together, rather than with the metastatic site ( Fig   1B) . The relative divergence in gene expression from the primary to the metastatic tumours was reflective of the disease latency period. Patient one with a recorded metastasis-free survival period of 11 years had the greatest difference in gene expression profile between the primary and metastatic tumours (Fig. 1B) . Patient two and patient three had shorter disease-free periods and correspondingly substantially less alterations in gene expression, suggesting that some of the genes necessary for successful progression are present in the primary tumour.
RNAseq data from the breast cancer sequential samples was analysed with breast cancer samples from The Cancer Genome Atlas by correspondence analysis of almost 16,000 genes ( Of note, the mTOR pathway which is a known predictor of endocrine resistance (14) , was found to be elevated in the liver metastases of patients one and three at the transcript level in comparison to the primary tumour ( Supplementary Fig. S2 ). Expression levels of phospho-mTOR and phosphop70S6 kinase in matched primary and metastatic tumours from endocrine treated patients confirmed activation of the mTOR pathway ( Supplementary Fig. S5 ).
Cell to cell communication is a common pathway in liver metastasis
Although at the gene level, patient heterogeneity was very apparent in the endocrine resistant metastatic tumours, a number of functional pathways were common to all three patients (Fig. 2C ).
Alterations in several cancer pathways including small cell lung carcinoma, renal cell carcinoma and pathways in cancer were observed. Of interest, pathways important in cell to cell interaction were represented in gene sets that were both enhanced and suppressed in the metastatic liver. found to be enhanced in the xenograft liver metastatic tissue compared with the primary (Fig. 3B ).
These data demonstrate that tamoxifen has the potential to contribute to the development of metastatic disease progression in endocrine resistant tumours. Analysis of the patient RNAseq data revealed that the majority of the identified upregulated DEGs were in fact elevated in metastatic tumours relative to both matched primary and nodal tumours (Fig. 3C ). These data suggest that for the majority of these genes, expression did not increase when the cells first moved away from the primary site to the node but did increase following treatment with tamoxifen, the latency period and intravasation of the distant organ. Remarkably, of the common DEGs displaying this pattern of expression (Supplementary Table S3 ), almost half have defined roles in cell to cell communication and cell structure ( Supplementary Fig. S6 ).
Cellular communication and cell structure proteins are evident at other metastatic sites
An extended cohort of matched primary and metastatic patient samples were employed to examine the RNA and protein expression of shared genes from the RNAseq data. The patient cohort included a range of metastatic sites including the liver, lung, bone and peritoneum of endocrine treated patients (Supplementary Table S4 ). Real-time PCR confirmed the elevated expression of genes in liver metastases relative to matched primary tumours (Fig. 3D ). Increases in gene expression were also detected at other metastatic sites ( Fig. 3D) . Signal pathways enriched at the metastatic site were also patient specific and closely related to the biology of the primary tumour. The ER/PgR/HER2 positive patient (patient three) displayed elevations in plasticity networks, including the WNT signalling pathways, whereas the ER/PgR positive, HER2 negative patient (patient one) had enhanced growth factor signalling. Increases in dedifferentiation signals and in particular induction of steroid receptor/growth factor receptor cross talk have been well described as mechanisms of tumour adaptability to endocrine treatment (16, 25, 26) . Furthermore elevations in key components of the mTOR pathway were observed in both patient one and patient three in metastatic liver tissue. Activation of the mTOR pathway has previously been associated in endocrine resistance (14, 27) and elevated expression of p-mTOR, p-4EBP1 and pp70S6K has been reported in metastatic tumours in comparison to matched primary tissue (28) .
The impact of sequential endocrine therapy in the treatment of endocrine resistant disease in patients however remains to be fully clarified. Though several clinical studies suggest that some metastatic patients respond to continued endocrine treatment, a subset of patients receives little or no benefit (29) (30) (31) . Here using endocrine resistant xenografts to model sequential treatment strategies we found that the development of distant metastasis was dependent on continued tamoxifen treatment. Though the molecular mechanisms driving this continued resistance have not been described to date, ex vivo studies demonstrating gain of function mutations in breast metastatic patient tumours following endocrine treatment suggest that ER may remain an important player (7) . In this study the majority of DEGs were elevated in the metastatic tumours relative to both the primary and the node, with little alteration observed between the primary and the Supplementary Figure S1 : Gene expression profiles of classic biomarkers in matched tumour samples from 3 patients. RNAseq data was mined for expression of the estrogen receptor (ESR1), the progesterone receptor (PgR), the human epidermal growth factor receptor 2 (ErbB2) and the proliferation marker Ki67 (MKI67). Gene expression in primary tumours largely reflected the protein expression observed by immunohistochemistry. For each patient, relative gene expression was compared between the metastatic liver tumour and the primary breast tumour. In total, 1,268 genes were identified as being significantly upregulated in at least one patient (fold change >1.5 with liver metastatic tumour showing higher expression than primary tumour, >50 counts per million in the metastatic tumour, expression in a normal liver sample < expression in the primary tumour). Enriched KEGG pathway terms were identified for each patient using a hypergeometric test from the GOstats package in Bioconductor.
The network map allows us to visualise the KEGG pathway terms which are common or unique.
Supplementary Figure S3: Network map showing the enriched KEGG pathways from downregulated differentially expressed genes (DEGs).
For each patient, relative gene expression was compared between the metastatic liver tumour and the primary breast tumour. In total, 2,606 genes were identified as being significantly downregulated in at least one patient (fold change >1.5 with liver metastatic tumour showing lower expression than primary tumour, >50 counts per million). Enriched KEGG pathway terms were identified for each patient using a hypergeometric test from the GOstats package in Bioconductor. The network map allows us to visualise the KEGG pathway terms which are common or unique.
Supplementary Figure S4 : Protein expression in matched primary and metastatic tissue from endocrine treated breast cancer patients. Immunohistochemistry analysis confirmed expression of phosphorylated growth factor signalling proteins, pERK1/2, pSTAT and pHER2 in both primary and metastatic tissue from a luminal A patient, Patient I (see Supplementary Table S4 for patient details). Protein expression of MCM4, a cell cycle protein, was confirmed in the matched primary and metastatic tumours from patient 2. Active β-catenin, a protein involved in the WNT signalling pathway, was detected in both primary and metastatic tumours from patient L, who presented with a luminal B2 primary tumour similar to patient 3 (see Supplementary Table S4 for patient details). Negative IgG controls for both rabbit and mouse antibodies are shown in the lower panel. Table S4 for patient details). Phosphorylated p-70S6K, a downstream target of mTOR, was also detected at the protein level in both the primary and matched tissue from patient I (Supplementary  Table S4 ).
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